Prognostic value of the combination of circulating tumor cells plus kras in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab

Clinical Colorectal Cancer

Volumn 12, Issue 4, 2013, Pages 280-286

  Sastre, Javier ^a   Vidaurreta, Marta ^a   Gómez, Auxiliadora ^b   Rivera, Fernando ^c   Massutí, Bartomeu ^d   López, Margarita Reboredo ^e   Abad, Albert ^f   Gallen, Manuel ^g   Benavides, Manuel ^h   Aranda, Enrique ^b   Rubio, Eduardo Díaz ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e UNIVERSITY OF A CORUÑA   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Bevacizumab; Capecitabine; Circulating tumor cells; Colorectal cancer; KRAS status; Oxaliplatin; Prognostic factors

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CIRCULATING TUMOR CELL; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; WILD TYPE;

BEVACIZUMAB; CAPECITABINE; CIRCULATING TUMOR CELLS; COLORECTAL CANCER; KRAS STATUS; OXALIPLATIN; PROGNOSTIC FACTORS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887319901     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.06.001     Document Type: Article

References (12)

1. S. Riethdorf, H. Fritsche, and V. Müller Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch System Clin Cancer Res 13 2007 920 928
2. S.J. Cohen, C.J.A. Punt, and N. Iannotti Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer J Clin Oncol 26 2008 3213 3221
3. J. Tol, M. Koopman, and M.C. Miller Circulating tumor cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents Ann Oncol 21 2010 1006 1012
4. J. Sastre, M.L. Maestro, and M.A. Gomez Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study Oncologist 17 2012 947 955
5. H.I. Hurwitz, J. Yi, and W. Ince The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer Oncologist 14 2009 22 28
6. E. Díaz-Rubio, A. Gomez, and B. Massuti Role of KRAS status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD Spanish Group Cooperative Study PLoS ONE 7 2012 e47345
7. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
8. J.R. Hecht, E. Mitchell, and T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
9. T.J. Price, J.E. Hardingham, and C.K. Lee Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer J Clin Oncol 29 2011 2675 2682
10. E. Diaz-Rubio, A. Gomez-España, and B. Massuti First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD Study Oncologist 17 2012 15 25
11. J. Sastre, M.L. Maestro, and J. Puente Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables Ann Oncol 19 2008 935 938
12. G. Masi, F. Loupakis, and L. Salvatore Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 2010 845 852